224 related articles for article (PubMed ID: 21856747)
1. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.
Asim M; Hafeez BB; Siddiqui IA; Gerlach C; Patz M; Mukhtar H; Baniahmad A
J Biol Chem; 2011 Oct; 286(43):37108-17. PubMed ID: 21856747
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
5. ARF represses androgen receptor transactivation in prostate cancer.
Lu W; Xie Y; Ma Y; Matusik RJ; Chen Z
Mol Endocrinol; 2013 Apr; 27(4):635-48. PubMed ID: 23449888
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
7. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
8. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
[TBL] [Abstract][Full Text] [Related]
9. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
Tian J; Lee SO; Liang L; Luo J; Huang CK; Li L; Niu Y; Chang C
J Biol Chem; 2012 Nov; 287(47):39954-66. PubMed ID: 23012352
[TBL] [Abstract][Full Text] [Related]
10. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
Dart DA; Spencer-Dene B; Gamble SC; Waxman J; Bevan CL
Endocr Relat Cancer; 2009 Dec; 16(4):1157-69. PubMed ID: 19635783
[TBL] [Abstract][Full Text] [Related]
11. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
12. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
13. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
[TBL] [Abstract][Full Text] [Related]
14. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
15. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor regulates SRC expression through microRNA-203.
Siu MK; Chen WY; Tsai HY; Yeh HL; Yin JJ; Liu SY; Liu YN
Oncotarget; 2016 May; 7(18):25726-41. PubMed ID: 27028864
[TBL] [Abstract][Full Text] [Related]
17. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.
Hu XD; Meng QH; Xu JY; Jiao Y; Ge CM; Jacob A; Wang P; Rosen EM; Fan S
Biochem Biophys Res Commun; 2011 Jan; 404(4):903-9. PubMed ID: 21172304
[TBL] [Abstract][Full Text] [Related]
18. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
19. A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.
Reeb CA; Gerlach C; Heinssmann M; Prade I; Ceraline J; Roediger J; Roell D; Baniahmad A
Endocrinology; 2011 Jun; 152(6):2174-83. PubMed ID: 21486935
[TBL] [Abstract][Full Text] [Related]
20. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]